OPEN END TURBO LONG - ZAI LAB | Real-time Bid/Ask 14:55:29 30/05/2024 BST | ||
| 0.79 EUR / 0.8 EUR | +1.92% |
|
| Current month | +30.00% | ||
| 1 month | +16.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZAI LAB LIMITED
Latest news about ZAI LAB LIMITED
More news
| Date | Price | Change |
|---|---|---|
| 30/05/24 | 0.78 | 0.00% |
| 29/05/24 | 0.78 | -6.02% |
| 28/05/24 | 0.83 | +7.79% |
| 24/05/24 | 0.77 | -13.48% |
| 23/05/24 | 0.89 | -12.75% |
Delayed Quote Börse Stuttgart
Last update May 30, 2024 at 02:39 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZAI LAB LIMITED |
| Issuer | Morgan Stanley |
| WKN | MG2HE3 |
| ISIN | DE000MG2HE36 |
| Date issued | 17/04/2024 |
| Strike | 10.12 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.18 € |
|---|---|
| Lowest since issue | 0.37 € |
| Spread | 0.01 € |
| Spread % | 1.25% |
Company Profile
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
-
Consensus: Zai Lab Limited
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.96
USD
Average target price
51.37
USD
Spread / Average Target
+186.04%
- Stock Market
- Certificates
- Certificat
